Drugs / HER-2/neu peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01219907 | Jun 2012 → Jun 2014 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01219907 ↗ |
| Action | Deplete | “Vaccines made from HER2 peptides may help the body build an effective immune response to kill tumor cells that express HER2.” NCT01219907 ↗ |
| Modality | Vaccine | “HER2 peptide vaccine” NCT01219907 ↗ |